The Second Clinical Medical College, Zhejiang Chinese Medical University, 310053 Hangzhou, Zhejiang, China.
Department of Rehabilitation Medicine, Hangzhou Medical College Affiliated People's Hospital (Zhejiang Provincial People's Hospital), 310014 Hangzhou, Zhejiang, China.
Discov Med. 2024 Jul;36(186):1354-1362. doi: 10.24976/Discov.Med.202436186.125.
Major depressive disorder (MDD) is a clinical condition that significantly impacts patients' physical and mental well-being, quality of life, and social functioning. The pathogenesis of MDD remains unclear, but accumulating evidence suggests a close relationship between gut microbiota and the occurrence and progression of MDD. Gut microbiota refers to the microbial community in the human intestine, which engages in bidirectional communication with the host via the "gut-brain axis" and plays a pivotal role in influencing the host's metabolism, immune system, endocrine system, and nervous system. Modulating gut microbiota entails restoring the balance and function of the intestinal flora through methods such as probiotic intake, fecal transplantation, and dietary intervention. Such modulation has been shown to effectively alleviate depressive symptoms in the host. This review synthesizes recent advancements in research on gut microbiota modulation for ameliorating depressive symptoms and can serve as a foundation for further exploration of the gut microbiota's role in MDD and its potential therapeutic benefits.
重度抑郁症（MDD）是一种严重影响患者身心健康、生活质量和社会功能的临床病症。MDD 的发病机制尚不清楚，但越来越多的证据表明肠道微生物群与 MDD 的发生和发展密切相关。肠道微生物群是指人类肠道中的微生物群落，通过“肠-脑轴”与宿主进行双向交流，在影响宿主代谢、免疫系统、内分泌系统和神经系统方面发挥着关键作用。调节肠道微生物群需要通过摄入益生菌、粪便移植和饮食干预等方法来恢复肠道菌群的平衡和功能。这种调节已被证明能有效地缓解宿主的抑郁症状。本综述综合了近年来关于调节肠道微生物群改善抑郁症状的研究进展，可为进一步探索肠道微生物群在 MDD 中的作用及其潜在的治疗益处提供基础。
